SIRUM is a social enterprise that focuses on expanding healthcare access by redistributing surplus medicine. The company's main service involves collecting unused medicine from health facilities, pharmacies, and other organizations, and redistributing it to those in need through community partners such as safety-net clinics and charitable pharmacies. SIRUM primarily serves the healthcare industry. It was founded in 2009 and is based in Palo Alto, California.
Expert Collections containing SIRUM
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
SIRUM is included in 1 Expert Collection, including Digital Health.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
SIRUM has filed 1 patent.
Pharmaceuticals policy, Pharmaceutical industry, Combination drugs, Life sciences industry, Clinical pharmacology
Pharmaceuticals policy, Pharmaceutical industry, Combination drugs, Life sciences industry, Clinical pharmacology
Latest SIRUM News
May 12, 2023
iStock BIOTECH STARTUP WITH ABBVIE, NAUREX and NU TIES OPENS EVANSTON LAB: A biotech startup with ties to local pharmaceutical companies and Northwestern University has opened a new lab in Evanston to use precision medicine to develop drugs for central nervous system disorders, including depression. Gate Neurosciences, an Indianapolis-based company developing drugs for neuropsychiatric and cognitive disorders, said this week that it is opening a 2,000-square-foot lab at NorthShore Evanston Hospital. "We're definitely really excited about what this means and the work that we're doing up there," says CEO and co-founder Mike McCully, a longtime biotech and business developer. "It's very much cutting-edge research work that we're doing in Evanston." So far, Gate Neurosciences' most promising drug is an oral depression therapy called Zelquistinel, which is expected to be in a confirmatory Phase II study by the end of the year, McCully says. Gate Neurosciences is also developing another depression drug called Apimostinel, an injectable therapy. While Gate Neurosciences is based in Indianapolis, its Chicago-area ties run deep. Part of its drug portfolio is based on therapies developed by former local biotech startup Naurex, which was creating depression drugs when it was acquired by AbbVie-owned Allergan in 2015. Gate has licensed the Naurex portfolio from North Chicago-based AbbVie to develop the drugs in the standalone company, and AbbVie holds an equity stake in the startup. Gate, which has about 12 employees, has a similar relationship with Indianapolis-based Eli Lilly. "We were in a position to go in and work with AbbVie to spin these assets out, and that really became the major focus of Gate Neurosciences at that point," McCully says. "This is a really exciting space in mental health and cognition . . . but it's a challenging space, too, and strategically, it was not a priority for AbbVie." AbbVie did not respond to a request for comment. According to McCully, AbbVie saw an opportunity to further develop and commercialize the Naurex portfolio at Gate because the startup's team is comprised of some of the researchers behind the original therapies. "To AbbVie, we really represented the people who knew the assets, who understood how to take them forward," McCully says. Gate's research team is led by Dr. Jeff Burgdorf, a biomedical engineering professor at Northwestern. Advising the team is Dr. John Donello, a former Allergan executive, and Dr. Joseph Moskal, a biomedical engineering professor at Northwestern and the scientist behind other local pharma companies, including Naurex. Moskal is also the brain behind Aptinyx, a biotech firm, which recently started shutting down after failing to get its drugs through clinical trials and approved by regulators. "It's a challenging market right now — finance-wise — in biotech," McCully says. "The Aptinyx shutdown is a key part of that and a reflection of how challenging the marketplace is right now." So far, Gate has raised about $30 million from investors including Innoviva, Luson BioVentures and BioCrossroads. Asked if Gate will raise more capital, McCully replies, "Always." "It's biotech. We are always in a position where we're looking and trying to attract more capital," he says. PHARMACY THAT SELLS SURPLUS DRUGS CHEAP OPENS IN ILLINOIS: Good Pill, a nonprofit pharmacy powered by donated surplus medicine and making use of the Illinois Drug Reuse Opportunity Program Act (I-DROP) is coming to Illinois, its parent company Sirum said in a statement. Good Pill touts home delivery of affordable medication, with savings of at least $150 a month possible, for anyone whose medication costs are too high, the statement said. That includes both people who do not have insurance or whose co-pays or deductibles are too high, the statement said. Sirum collects unopened and unexpired non-opioid surplus medicine that would otherwise go to waste and redistributes them, the statement said. Good Pill customers' first order is $6, regardless of the number of medications and with or without insurance and follows up with medications for $2 for a 30-day supply or $6 for a 90-day supply, which can be covered by the patient or provider, the statement said. I-DROP provides for both prescription drugs and over-the-counter drugs to be donated for redistribution, and Good Pill health care professionals check for safety before dispensing, the statement said. The pharmacy carries some 500 different medications, including medication for hypertension, Type II diabetes, depression and more, it said. "Too many Illinoisans are struggling to pay for their medicines. They're splitting pills, paying the rent late, or just not filling their prescriptions at all," said state Rep. Will Guzzardi, D-Chicago, chief sponsor of the bill in 2021. "That's unacceptable, and we're doing something about it. The transformative new Illinois Drug Reuse Opportunity Program and leading organizations like Sirum and Good Pill are going to provide lifesaving medicines for virtually no cost to those in need, and I'm so excited to see this important law becoming a reality in our state." TEMPUS LAWSUIT CLAIMS FORMER EXECUTIVE TOOK SECRETS TO COMPETITION: Artificial intelligence and precision medicine company Tempus has filed a lawsuit that accuses a former executive of taking the company's proprietary information to a new job with a competitor and "fraudulently inducing Tempus to issue him a new employment agreement with no post-employment restrictive covenants." The lawsuit, filed in the U.S. District Court for the Northern District of Illinois, Eastern Division, alleges that Sandeep Pawar left Tempus for a similar role with Caris Life Sciences after copying highly confidential and competitively sensitive documents, making Pawar " uniquely positioned to try to improperly leverage this knowledge to attempt to bring Caris to the next level in a highly specialized and competitive industry." Attempts to contact Pawar were unsuccessful. Caris Life Sciences did not respond to a request for comment. Tempus said in the lawsuit that Pawar asked for a new Confidentiality, Intellectual Property, & Protective Covenants Agreement (CIPPA) in April 2023, then left about two weeks later. It claims Pawar falsely represented he needed a new CIPPA based on a request by the U.S. Citizenship & Immigration Services related to his application for permanent residency." Pawar's representations were, in reality, outright lies designed to obtain a CIPPA without restrictive covenants so he would be "free" to join Caris," the lawsuit said. "Two weeks later, Pawar printed out a trove of highly sensitive and confidential documents containing pricing and pricing guidelines, Tempus' customer information, project proposals, and statements of work, among other proprietary documents and information, from Tempus' network," the lawsuit alleges. "The very next day, he tendered his resignation to Tempus to take a role with Caris as its vice president, data strategy and solutions where he would 'be getting back into data,' and he acknowledged to his former Tempus colleagues that Caris hired him to perform a similar, data-focused role at Caris." Chicago-based Tempus uses large amounts of patient data and artificial intelligence in working with health care providers to develop personalized medical treatments for cancer and other diseases. The company described Caris as one of its very few direct competitors. "In recent years, Caris has launched its own version of a molecular and clinical database that is similar to what Tempus has operated for years," the lawsuit said. The lawsuit asks the court to immediately enjoin Pawar from working for Caris. Tempus stated that it hired Pawar in August 2019 as its director, strategic operations in Chicago. After a number of changes in title and roles, the lawsuit said, around Feb. 24, 2022, Tempus promoted Pawar to the role of senior director, data growth and operations strategy. BILL TARGETING DECEPTIVE PRACTICES BY ANTI-ABORTION PREGNANCY CENTERS PASSES: The General Assembly has passed the Deceptive Practices of Limited Services Pregnancy Centers bill, which is widely expected to be signed by Illinois Gov. J.B. Pritzker. The bill is designed to police practices by Limited Service Pregnancy Centers (LSPC), allowing the Illinois attorney general's office to fine a center up to $50,000 for deceptive practices. LSPCs, also known as crisis pregnancy centers, are often run by anti-abortion groups who seek to dissuade pregnant women from having abortions. State Rep. Blaine Wilhour, R-Beecher City, said the law is "using the power of government to target people with whom they disagree." He said there has been no evidence provided to suggest crisis pregnancy centers engage in deceptive practices. Raoul said in a statement he witnessed deceptive tactics firsthand while touring a Planned Parenthood health center. "People who appeared as though they might work there were outside attempting to divert us away from the health center," Raoul said in the statement. "Patients report going to crisis pregnancy centers — sometimes even receiving exams and ultrasounds — thinking they were visiting a different clinic that offers the full range of reproductive care. This is an extreme violation of trust and patient privacy that should not occur in our state." Limited Service Pregnancy Centers "routinely spread misinformation and use deceptive practices that lead to confusion, anxiety and even physical harm for our patients," Jennifer Welch, president and CEO of Planned Parenthood of Illinois, said in a statement applauding the bill. Illinois Right to Life and other anti-abortion groups in the state have complained the bill does not provide adequate definition, clarification or examples of what behaviors would be considered deceptive. HOW MED SCHOOLS FARED IN RANKINGS THAT THEY'RE UNHAPPY WITH: U.S. News & World Report rankings for medical and law schools were released Thursday and Northwestern's Feinberg School of Medicine rose to No. 13 from No. 17 a year ago in the medical school rankings for research. UChicago's Pritzker School of Medicine moved up to No. 18 from No. 20 last year, despite announcing it would withdraw from the rankings in January. Read more. The Feinberg medical school this year tied with schools at the Mayo Clinic, Michigan and the universities of Pittsburgh and Washington. UChicago tied with the med schools at UCLA and Mount Sinai at No. 18. When it pulled out at the end of January, UChicago's Pritzker School of Medicine said the publication lacks "transparent, meaningful and usable data" that medical students deserve. NU's Feinberg School of Medicine declined to comment on their counterpart's decision and has made no public announcement on its intentions to leave the rankings. The University of Illinois medical school ranked No. 58, tied with the University of Nebraska. Rush University ranked No. 68, tied with Rutgers Robert Wood Johnson Medical School in New Jersey and Hofstra University/Northwell Health in New York. AT A GLANCE A drug to treat the agitation associated with Alzheimer's disease, co-developed by Lundbeck and Otsuka Pharmaceutical has received approval by the FDA. The companies said in a statement that the FDA has approved the supplemental New Drug Application of Rexulti. It is the only pharmacological treatment approved in the U.S. for agitation associated with dementia due to Alzheimer's disease, the statement said. The FDA previously granted priority review for the sNDA, a designation for a drug application that represents a significant improvement in the safety and/or effectiveness of the treatment, diagnosis or prevention of a serious medical condition. Clinical trial data showed the drug was well-tolerated with a low incidence of discontinuations and a safety profile consistent with the known safety profile of brexpiprazole in other indications, the statement said. Lundbeck is based in Deerfield, Otsuka is based in Princeton, N.J. The company seeking to track patient's microbiome through the use of a "smart bathroom" has closed on an oversubscribed $3 million funding round. Chicago-based BiomeSense said in a statement that the round was led by Bluestein Ventures and includes new investor Harvest Ridge Capital along with participation from existing investors SOSV and Seerave Foundation. The financing will support a commercial launch, anticipated within the year, the statement said. BiomeSense is developing GutLab which integrates precision measurement and analytics to provide data on human microbiome. Cook County is forgiving almost $80 million in medical debt for about 73,000 residents in a program paid for by American Rescue Plan Act dollars. The county has already erased $25 million in medical debt for 45,000 residents and will soon abolish $54 million more for nearly 28,000 residents. More debt is slated to be forgiven in coming months. Preckwinkle's office says the program, launched earlier this year, could abolish up to $1 billion in medical debt by 2026, when ARPA funding expires. Read more. While monkeypox is no longer a global health emergency according to the WHO , Chicago is ground zero for a new outbreak of the disease in the U.S. Crain's reported of a steep rise in cases there were a total of seven cases during the week ending April 29 and five more cases in the week ended May 6. Public health officials are still urging anyone at risk for the disease, which is especially high among men who have multiple or anonymous male sexual partners, to get vaccinated, the Chicago Department of Public Health officials say. Chicago-based hearing aid company Beltone said in a statement this week that MLM Hearing has acquired 50 Beltone locations in the U.S. The move, which makes MLM independent Beltone distributors in the U.S., adds to MLM's 29 Beltone Canada locations. It's the only distributor to operate in both the U.S. and Canada. The Pulmonary Fibrosis (PF) Foundation is warning patients to use only FDA-approved oxygen delivery devices. Following a study which found nonprescription, non-FDA approved oxygen supply devices may not deliver reliable amounts of oxygen, the Chicago-based group's medical advisory board said. While PF patients often prefer portable oxygen concentrators, "non-FDA approved portable oxygen concentrators available online are not the solution," the foundation said in a statement. According to study results published in Respiratory Care, only one of three of the OTC portable concentrators researchers tested was potentially of use by patients requiring ambulatory oxygen. PEOPLE ON THE MOVE • Tempus has named Dr. Ezra Cohen as chief medical officer of oncology and Dr. Norman E. "Ned" Sharpless as a senior strategic advisor to its leadership team. Cohen was most recently the chief of the division of hematology-oncology as well as the associate director of clinical science at UC San Diego Moores Cancer Center. He also led the Precision Immunotherapy Clinic and co-directed the San Diego Center for Precision Immunotherapy at UCSD. Before UCSD, Cohen spent 15 years at the University of Chicago, where he was the co-director of the Head and Neck Cancer Program as well as program director of the Hematology/Oncology Fellowship Program. Sharpless was most recently the director of the National Cancer Institute, part of the National Institutes of Health, a position he held from 2017 to 2022. He also served as acting commissioner for food and drugs at the FDA in 2019. • On the heels of announcing it was set to open its new manufacturing plant in Kenosha County, Wis., Nexus Pharmaceuticals has announced the appointment of Edgar Lee and Mike Warmuth to the company's board of directors. Lee is the founder and managing member of Sagent Group. Warmuth was most recently an operating partner at EW Healthcare Partners from 2018 to 2022. Prior to EW Healthcare Partners, Warmuth was at Abbott Laboratories, where he led the established pharmaceuticals division. • Erik Miller has been named president and general manager at MedHQ, the Chicago-based provider of technology-enabled expert services to health care providers. Miller most recently served as interim president of Anesthesia Medicine at Ventra Health as well as serving as the company's chief strategy and business development officer. RECOMMENDED FOR YOU
SIRUM Frequently Asked Questions (FAQ)
When was SIRUM founded?
SIRUM was founded in 2009.
Where is SIRUM's headquarters?
SIRUM's headquarters is located at 3000 El Camino Real, Palo Alto.
What is SIRUM's latest funding round?
SIRUM's latest funding round is Grant - II.
How much did SIRUM raise?
SIRUM raised a total of $490K.
Who are the investors of SIRUM?
Investors of SIRUM include Goldman Sachs Gives, Visible Connect, Women Startup Challenge, Y Combinator, Google.org and 3 more.